Skip to content
Buy This GLP
← Research
Evidence

Real-World Tirzepatide Dosing: 74.2% Under 10 mg at the Sixth Fill

In a 20,998-person claims study, 74.2% of people with a sixth fill received a dose below 10 mg. The separate utilization analysis found 55.4% persistence at six months.

Editorial profile: Neil SandersBuy This GLP Editorial Team4 min read
At the sixth prescription fill74 in 100 fills were under 10 mgAmong patients with a sixth fill.Optum claims cohort, 2022–2023.

A claims study of tirzepatide found that 74.2% of patients with a sixth fill received a dose below 10 mg [1]. As you compare prices that change by dose, ask what each prescribed strength costs. A pharmacy claim records the dose dispensed and cannot verify how much a patient used.

What the sixth fill showed

The study identified 20,998 adults without type 2 diabetes who started tirzepatide between May 2022 and September 2023. The utilization analysis used a smaller group (n = 3,459). At the sixth fill, the most common strength was 5 mg (33.0%), and 25.8% filled 10 mg or more.

The six-month cost comparison multiplies the published monthly rate by six. If the rate changes by dose, use the quoted price for each fill to estimate what you’ll pay.

How many continued at six months

The study counted 55.4% of the utilization cohort as persistent at six months using a 60-day gap to define discontinuation. A further 30.8% switched to a different weight-loss medication or restarted tirzepatide after stopping. Our review of longer-term treatment persistence covers other populations and follow-up periods. Those estimates answer a different question from this six-month claims analysis.

Who was included in the weight-loss estimate

The effectiveness analysis included 239 people with no prior GLP-1 use who stayed on tirzepatide for at least six months and had weights recorded at baseline and six months. They lost an average of 11.9% of baseline weight. The study did not randomly assign doses, so that average cannot establish how much weight people lose at any particular strength.

If a seller asks you to pay up front, the prepayment comparison helps separate the amount due from the advertised monthly average. Check the refund terms if your prescription, coverage, or ability to continue changes.

Frequently asked

What dose did patients fill at their sixth prescription?
Among patients with a sixth fill, 74.2% filled a dose below 10 mg. That records what the pharmacy dispensed.
How many were still taking it?
Persistence was 55.4% at six months. A further 30.8% switched to another anti-obesity medication or GLP-1, or restarted tirzepatide after stopping.
Who was included in the six-month weight-loss estimate?
The average weight loss was 11.9% among 239 people with no prior GLP-1 use who stayed on tirzepatide for six months and had weight measurements at both time points. It was a group average across doses.

Sources

  1. [1] Hankosky ER, et al. (2025). Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database Diabetes, Obesity and Metabolism. PMID 39996368

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence